基于循证证据的麻醉科处方前置审核规则精细化设置及效果   评价

邢晓敏; 李祥鹏; 王心怡; 魏丽娜; 李文静; 李静

doi:10.6039/j.issn.1001-0408.2024.14.03

您当前的位置：

首页 >

文章列表页 >

基于循证证据的麻醉科处方前置审核规则精细化设置及效果评价

药事管理 | 更新时间：2024-07-25

- 基于循证证据的麻醉科处方前置审核规则精细化设置及效果评价
- Practice and effect evaluation of refined setting of evidence-based reference prescription pre-audit rules in anesthesiology department
- 中国药房 2024年35卷第14期页码：1690-1695
- 作者机构：
  
  青岛大学附属医院药学部，山东青岛　266000
- 作者简介：
  
  主管药师，硕士。研究方向：疼痛药物治疗。E-mail：xingxiaomin@qdu.edu.cn
  主任药师，硕士。研究方向：医院药学、药事管理。电话：0532-82911566。E-mail：lijing7112@126.com
- 基金信息：
  
  国家卫生健康委医院管理研究所医院药学高质量发展研究项目(NIHAYS2308)
- DOI：10.6039/j.issn.1001-0408.2024.14.03
  中图分类号： R971;R969.3
- 纸质出版日期：2024-07-30，
  
  收稿日期：2024-01-19，
  
  修回日期：2024-04-12，
- 稿件说明：
扫描看全文
邢晓敏,李祥鹏,王心怡等.基于循证证据的麻醉科处方前置审核规则精细化设置及效果评价 ^Δ[J].中国药房,2024,35(14):1690-1695.

XING Xiaomin,LI Xiangpeng,WANG Xinyi,et al.Practice and effect evaluation of refined setting of evidence-based reference prescription pre-audit rules in anesthesiology department[J].ZHONGGUO YAOFANG,2024,35(14):1690-1695.
邢晓敏,李祥鹏,王心怡等.基于循证证据的麻醉科处方前置审核规则精细化设置及效果评价 ^Δ[J].中国药房,2024,35(14):1690-1695. DOI： 10.6039/j.issn.1001-0408.2024.14.03.

XING Xiaomin,LI Xiangpeng,WANG Xinyi,et al.Practice and effect evaluation of refined setting of evidence-based reference prescription pre-audit rules in anesthesiology department[J].ZHONGGUO YAOFANG,2024,35(14):1690-1695. DOI： 10.6039/j.issn.1001-0408.2024.14.03.

摘要

目的

优化麻醉科处方前置审核规则，提高审方质量和合理用药水平。

方法

统计并分析2023年4月1日至30日青岛大学附属医院（以下简称“我院”）处方前置审核系统中麻醉科的住院医嘱，对不合理用药问题进行分类统计与循证查询，结合我院现执行的《麻醉科临床路径用药规范》，对审核规则进行精细化设置，并建立审核管理与沟通反馈流程。对规则精细化设置后（2023年5－12月）与设置前（2023年4月）的每月审核医嘱总数、预审弹窗医嘱数、系统拦截率、系统审核后医师修改率、药师审核率、医嘱合理率进行比较，对设置后与设置前（2022年5－12月）的麻醉科次均药费进行环比比较。

结果

麻醉科不合理用药问题主要包括适应证不适宜、给药途径不适宜、用法用量不适宜、配伍不适宜、特殊人群用药问题、围手术期不合理用药问题。规则精细化设置后，麻醉科预审弹窗医嘱数随时间延长明显减少，经过不断完善后逐步达到平稳状态。与设置前比较，规则精细化设置后系统拦截率显著提高（

＜0.001），系统审核后医师修改率显著提高（

＜0.001），药师审核率显著下降（

＜0.001）；2023年5－12月医嘱合理率与月份存在线性趋势（

＜0.001）。设置后与设置前相比，麻醉科次均药费由平均720.72元下降至平均528.21元，降幅为26.71%。

结论

基于循证证据精细化设置麻醉科处方前置审核规则，可显著提高处方审核质量，促进合理用药，节约患者医疗费用。

Abstract

OBJECTIVE

To optimize the pre-audit rules for anesthesia prescriptions， improve the audit quality and rational drug use.

METHODS

The inpatient medical orders of anesthesia department from prescription pre-audit system of the Affiliated Hospital of Qingdao University （hereinafter referred to as “our hospital”） were analyzed from April 1 to 30， 2023. The classification statistics and evidence-based inquiry were carried out for irrational drug use issues； combined with our hospital’s current implementation of the

Anesthesiology Clinical Pathway Medication Standards

， the audit rules were set in details， and audit management and communication feedback processes were established. The total number of monthly audited orders， the number of pre-audit pop ups， system interception rate， physician modification rate after system audit， pharmacist audit rate， and reasonable rate of medical orders after refined setting of rules （May-December in 2023） were compared with before setting （April in 2023）； the average medication cost per anesthesia session after refined setting of rules was also compared with before setting （May-December in 2022）.

RESULTS

Irrational drug use in the anesthesia department mainly included inappropriate indications， inappropriate administration routes， inappropriate usage and dosage， inappropriate compatibility， medication problems in special populations， and improper medication during the perioperative period. After the refinement of the rules， the number of pre-audit pop ups in the anesthesia department significantly decreased over time， and gradually reached a stable state after continuous improvement. Compared with before setting， the system interception rate after the refinement of rules （

＜0.001）， physician modification rate after system

audit （

＜0.001） both increased significantly， while the pharmacist audit rate significantly decreased （

＜0.001）. There was a linear trend between the reasonable rate of medical orders and the month from May to December in 2023 （

＜0.05）. Compared with before the setting， the average medication cost of anesthesia per session decreased from 720.72 yuan to 528.21 yuan， with a decrease of 26.71%.

CONCLUSIONS

Based on evidence-based reference， refining pre-audit rules for anesthesia prescriptions can significantly improve the quality of prescription examination， promote rational drug use， and save patient’s medical expenses.

关键词

处方前置审核麻醉科循证证据审核规则合理用药

Keywords

anesthesia departmentevidence-based referenceaudit rulesrational drug use

references

BICKHAM P，GOLEMBIEWSKI J，MEYER T，et al. ASHP guidelines on perioperative pharmacy services[J]. Am J Health Syst Pharm，2019，76（12）：903-820.

国家卫生健康委员会，国家中医药管理局，中央军委后勤保障部. 医疗机构处方审核规范[EB/OL].（2018-07-10）[2024-01-10]. http：//www.nhc.gov.cn/yzygj/s7659/201807/de5c7c9116b547af819f825b53741173.shtmlhttp://www.nhc.gov.cn/yzygj/s7659/201807/de5c7c9116b547af819f825b53741173.shtml.

National Health Commission，State Administration of Traditional Chinese Medicine，Logistics Support Department of the Central Military Commission.Prescription review standards for medical institutions[EB/OL].（2018-07-10）[2024-01-10]. http：//www.nhc.gov.cn/yzygj/s7659/2018-07/de5c7c9116b547af819f825b53741173.shtmlhttp://www.nhc.gov.cn/yzygj/s7659/2018-07/de5c7c9116b547af819f825b53741173.shtml.

程凯，王欢，杜春晓，等. 信息系统辅助抗肿瘤药物处方审核分析[J]. 医药导报，2024，43（1）：47-53.

CHENG K，WANG H，DU C X，et al. Analysis of review of anti-tumor drug prescriptions assisted by information system[J]. Her Med，2024，43（1）：47-53.

张婷，顾婕，丁兰萍，等. 医疗机构中药处方前置审核规则的优化与实践[J]. 中国药房，2022，33（12）：1506-1512.

ZHANG T，GU J，DING L P，et al. Optimization and practice in pre-review rules of traditional Chinese medicine prescription in medical institutions[J]. China Pharm，2022，33（12）：1506-1512.

LAWTON J S，TAMIS-HOLLAND J E，BANGALORE S，et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization：a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. Circulation，2022，145（3）：e18-e114.

中华医学会心血管病学分会，中华心血管病杂志编辑委员会. 非心脏外科手术围手术期心血管疾病管理中国专家共识[J]. 中华心血管病杂志，2023，51（10）：1043-1055.

Cardiovascular Branch of the Chinese Medical Association，Editorial Committee of the Chinese Journal of Cardiovascular Disease. Chinese expert consensus on peri-operative cardiovascular assessment and management of patients undergoing non-cardiac surgery[J]. Chin J Cardiol，2023，51（10）：1043-1055.

广东省药学会. 关于发布《超药品说明书用药目录（2023年版）》的通知[EB/OL].（2023-07-04）[2024-01-10]. http：//www.sinopharmacy.com.cn/notification/2797.htmlhttp://www.sinopharmacy.com.cn/notification/2797.html.

Guangdong Pharmaceutical Association.Notice on issuing the Catalogue of Medications for Off-Label Drug Use（2023 Edition）[EB/OL].（2023-07-04）[2024-01-10]. http：//www.sinopharmacy.com.cn/notification/2797.htmlhttp://www.sinopharmacy.com.cn/notification/2797.html.

PLAUD B，BAILLARD C，BOURGAIN J L，et al. Guidelines on muscle relaxants and reversal in anaesthesia[J]. Anaesth Crit Care Pain Med，2020，39（1）：125-142.

黑子清，黄文起，刘克玄，等. 麻醉前应用抗胆碱能药物的广东省专家共识：2021版[J]. 广东医学，2021，42（11）：1290-1294.

HEI Z Q，HUANG W Q，LIU K X，et al. The 2021 edition of expert consensus of Guangdong province on the use of anticholinergic drugs before anesthesia[J]. Guangdong Med J，2021，42（11）：1290-1294.

徐建国，黄宇光，邓小明，等. 地佐辛术后镇痛专家建议：2018[J]. 临床麻醉学杂志，2018，34（7）：712-715.

XU J G，HUANG Y G，DENG X M，et al. Expert advice on postoperative analgesia with dezocine：2018[J]. J Clin Anesthesiol，2018，34（7）：712-715.

合理用药国际网络中国中心组临床安全用药组，中国药理学会药源性疾病学专业委员会，药物不良反应杂志社，等. 医疗机构围手术期镇痛药使用的风险防范与管理指导原则[J]. 药物不良反应杂志，2022，24（8）：396-403.

The International Network of Rational Drug Use China Center Group Clinical Safety Drug Use Group，the Professio-nal Committee of Pharmacological Diseases of the Chinese Pharmacological Society，Journal of Adverse Drug Reactions，et al.Guidelines for prevention and management of perioperative analgesics use in medical institutions[J]. Adverse Drug React J，2022，24（8）：396-403.

广东省药学会. 临床药师术后疼痛管理指引[J]. 今日药学，2019，29（4）：217-227.

Guangdong Pharmaceutical Association.Guidelines for postoperative pain management of clinical pharmacists[J]. Pharm Today，2019，29（4）：217-227.

蔡学菊，刘立民，王羡欠，等. 全程化手术室麻醉药品管理体系的构建[J]. 药品评价，2023，20（5）：599-603.

CAI X J，LIU L M，WANG X Q，et al. Construction of a comprehensive narcotic drugs management system for ope-rating rooms[J]. Drug Eval，2023，20（5）：599-603.

张旭锋，史香芬，卢晓静，等. 基于门诊处方前置审核系统的麻醉药品和精神药品用药规则精细化设置与实施效果评价[J]. 中国医院药学杂志，2022，42（9）：935-939.

ZHANG X F，SHI X F，LU X J，et al. Fine setting and implementation effects evaluation of the use rules for narcotic drugs and psychotropic drugs based on outpatient prescription pre-review system[J]. Chin J Hosp Pharm，2022，42（9）：935-939.

XIE H，ZHANG H X，PENG J，et al. Prospective prescription review system promotes safe use of analgesics，improves clinical outcomes，and saves medical costs in surgical patients：insights from Nanjing Drum Tower Hospital[J]. Adv Ther，2022，39（1）：441-454.

陈慧，王诗卉，张东肃，等. 北京某三级综合医疗机构实施处方前置审核效果[J]. 医药导报，2020，39（9）：1203-1205.

CHEN H，WANG S H，ZHANG D S，et al. Effect and practice of pre-prescription review in a third-level medical institution in Beijing[J]. Her Med，2020，39（9）：1203-1205.

FAN X C，CHEN D X，BAO S W，et al. Prospective prescription review system correlated with more rational PPI medication use，better clinical outcomes and reduced PPI costs：experience from a retrospective cohort study[J]. BMC Health Serv Res，2023，23（1）：1014.

魏娜，吴朝阳，陈伦灼，等. 基于循证证据的我院出院带药处方前置审核系统的运行实践[J]. 中国药房，2020，31（15）：1910-1915.

WEI N，WU Z Y，CHEN L Z，et al. Evidence-based operation practice of pre-audit system of discharged prescriptions in our hospital[J]. China Pharm，2020，31（15）：1910-1915.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

马昔腾坦相关不良事件信号的挖掘与分析 ^Δ

北京市属医院住院医嘱点评审核工作现状调查与分析

县域医共体以抗感染临床药师为主体的抗菌药物使用管理模式应用及评价

抗抑郁药品临床综合评价专家共识

泊沙康唑联用PPI对恶性血液病患者血药浓度和侵袭性真菌感染的影响